TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer

Inclusion Criteria: * Age \>= 18 years old * ECOG performance status 0-2 * Non-squamous cell type non-small cell lung cancer (NSCLC) * Stage IV, Stage IIIB cannot be treated with curative intent or Relapsed after surgery or radiation therapy * No prior chemotherapy except adjuvant chemotherapy and concurrent chemoradiation treatment. The last dose of adjuvant chemotherapy should be at least 6 months earlier from randomization, and the regimen should not contain docetaxel or pemetrexed. * No prior immunotherapy, biologic therapy * Measurable lesion with Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 * Hemoglobin \>=9.0g/dl, Platelet \>=100,000/uL, neutrophil \>=1,500 /uL Creatinine \<=1.5 x upper normal limit or creatinine clearance \>=60 mL/min Bilirubin \<=1.5 x upper normal limit, Transaminases \<=2 x upper normal limit Alkaline phosphatase \<=2 x upper normal limit * Written informed consent Exclusion Criteria: * Pregnancy, Lactating woman * Woman in child bearing age who refuses to do pregnancy test * Moderate or greater than grade 1 motor or sensory neurotoxicity * Hypersensitivity to taxane * Comorbidity or poor medical conditions * Other malignancy (except cured basal cell carcinoma or uterine cervical carcinoma in situ) * Concurrent treatment with other investigational drugs within 30 days before randomization * Active treatment with other anticancer chemotherapy * EGFR mutation (exon 19 deletion, L858R, L861Q, G719A/C/S)